Back to Trials
NCT01587300Recruiting

Neuroblastoma Biology Study

New Approaches to Neuroblastoma Therapy Consortium

Start Date

7/1/2011

Completion Date

12/1/2099

Summary

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

Detailed Description

The purposes of this study are: To establish a storage place or bank of samples of blood, bone marrow, and/or tumor, and molecular components isolated from these samples from children with neuroblastoma. The stored specimens will be shared with laboratory researchers studying high risk neuroblastoma. To collect clinical data (such as treatments received, date of diagnosis, tumor stage, etc) and radiology scans to provide this information as needed for the laboratory studies to be done on the specimens. To obtain neuroblastoma tumor cells from tumor tissue, bone marrow, and/or blood to use to start cell lines, or tumor cells that will keep growing in the laboratory. These cell lines will be shared with laboratory researchers studying high risk neuroblastoma.

Eligibility Criteria

Age Range: No minimum to 99 years

Inclusion Criteria: * Patients must be greater than or 31 days of age. * Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. * All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted. * Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized. Exclusion Criteria: * There are no exclusion criteria on this study.

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Neuroblastoma

Locations

Children's Hospital Los Angeles

Los Angeles, California 90027-0700

United States

Lucille Salter Packer Children's Hospital, Stanford University

Palo Alto, California 94305

United States

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California 94115

United States

Children Hospital of Colorado

Aurora, Colorado 80045

United States

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus

Atlanta, Georgia 30322

United States

University of Chicago, Comer Children's Hospital

Chicago, Illinois 60637

United States

Children's Hospital Boston

Boston, Massachusetts 02115

United States

C.S Mott Children's Hospital

Ann Arbor, Michigan 48109

United States

University of North Carolina

Chapel Hill, North Carolina 27599

United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio 45229-3039

United States

Nationwide Children's Hospital

Columbus, Ohio 43205

United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania 19104-4318

United States

St. Jude Children's Research Hospital

Memphis, Tennessee 38105

United States

University of Texas Southwestern

Dallas, Texas 75235

United States

Cook Children's Medical Center - Fort Worth

Fort Worth, Texas 76104

United States

Seattle Children's Hospital

Seattle, Washington 98105

United States

Hospital for Sick Children

Toronto, Ontario M5G 1X8

Canada